New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models.
Animals
Anti-HIV Agents
/ pharmacology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
HIV Infections
/ drug therapy
HIV-1
/ drug effects
Lymphocyte Depletion
Models, Animal
Primates
Simian Immunodeficiency Virus
/ drug effects
Virus Activation
/ drug effects
Virus Latency
/ drug effects
HIV-1 cure
latency reversing agents
nonhuman primates
shock and kill
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
06 08 2021
06 08 2021
Historique:
received:
29
06
2021
revised:
26
07
2021
accepted:
03
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
5
2
2022
Statut:
epublish
Résumé
Antiretroviral therapy (ART) controls human immunodeficiency virus 1 (HIV-1) replication and prevents disease progression but does not eradicate HIV-1. The persistence of a reservoir of latently infected cells represents the main barrier to a cure. "Shock and kill" is a promising strategy involving latency reversing agents (LRAs) to reactivate HIV-1 from latently infected cells, thus exposing the infected cells to killing by the immune system or clearance agents. Here, we review advances to the "shock and kill" strategy made through the nonhuman primate (NHP) model, highlighting recently identified latency reversing agents and approaches such as mimetics of the second mitochondrial activator of caspase (SMACm), experimental CD8+ T cell depletion, immune checkpoint blockade (ICI), and toll-like receptor (TLR) agonists. We also discuss the advantages and limits of the NHP model for HIV cure research and methods developed to evaluate the efficacy of in vivo treatment with LRAs in NHPs.
Identifiants
pubmed: 34452425
pii: v13081560
doi: 10.3390/v13081560
pmc: PMC8402914
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI133706
Pays : United States
Références
Clin Infect Dis. 2021 Jun 1;72(11):e815-e824
pubmed: 33043969
J Virol. 2019 Dec 12;94(1):
pubmed: 31597757
J Virol. 2010 Mar;84(6):2913-22
pubmed: 20032180
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
J Infect Dis. 2010 Jul 1;202(1):161-70
pubmed: 20497048
J Infect Dis. 2015 Nov 1;212(9):1387-96
pubmed: 25883388
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73
pubmed: 9671771
J Virol. 2021 Feb 10;:
pubmed: 33568515
Sci Rep. 2019 Aug 19;9(1):12078
pubmed: 31427605
Viruses. 2019 Jan 27;11(2):
pubmed: 30691203
Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4
pubmed: 31295427
AIDS. 2019 Dec 1;33 Suppl 2:S181-S188
pubmed: 31789817
PLoS Pathog. 2017 May 4;13(5):e1006359
pubmed: 28472156
Curr HIV/AIDS Rep. 2021 Apr;18(2):117-127
pubmed: 33433817
J Clin Invest. 2013 Feb;123(2):594-9
pubmed: 23281401
J Virol. 2019 Aug 28;93(18):
pubmed: 31217249
PLoS One. 2020 Nov 2;15(11):e0241667
pubmed: 33137166
Immunity. 2016 Sep 20;45(3):656-668
pubmed: 27653601
Nature. 2013 Oct 3;502(7469):100-4
pubmed: 24025770
Sci Transl Med. 2018 May 2;10(439):
pubmed: 29720451
Nat Med. 2014 Feb;20(2):139-42
pubmed: 24412925
Methods Mol Biol. 2005;304:3-15
pubmed: 16061962
Nat Methods. 2015 May;12(5):427-32
pubmed: 25751144
Nat Commun. 2021 May 17;12(1):2866
pubmed: 34001890
J Virol. 2018 Oct 29;92(22):
pubmed: 30185596
J Clin Invest. 2021 Apr 15;131(8):
pubmed: 33630764
PLoS Pathog. 2020 Oct 26;16(10):e1008954
pubmed: 33104758
Immunogenetics. 2007 May;59(5):367-75
pubmed: 17334754
AIDS. 2003 Sep 5;17(13):1871-9
pubmed: 12960819
Nat Med. 2016 Aug;22(8):839-50
pubmed: 27400264
Nature. 2020 Feb;578(7793):154-159
pubmed: 31969705
Science. 2014 Jul 11;345(6193):169-74
pubmed: 25013067
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
J Virol. 2018 Jun 29;92(14):
pubmed: 29720521
J Med Primatol. 2015 Oct;44(5):296-300
pubmed: 26101933
Nature. 2016 Dec 8;540(7632):284-287
pubmed: 27841870
J Virol. 2004 Dec;78(24):13553-61
pubmed: 15564466
Nat Med. 2020 Apr;26(4):519-528
pubmed: 32284611
Immunol Rev. 2012 Mar;246(1):125-40
pubmed: 22435551
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2575-E2584
pubmed: 29483265
Curr Opin HIV AIDS. 2016 Jul;11(4):432-41
pubmed: 27152962
Front Immunol. 2019 Oct 15;10:2450
pubmed: 31681325
J Virol. 2018 Aug 29;92(18):
pubmed: 29997216
Nature. 2014 Aug 7;512(7512):74-7
pubmed: 25042999
Nat Commun. 2018 Dec 21;9(1):5429
pubmed: 30575753
AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1247-57
pubmed: 10957722
J Virol. 2013 Jun;87(11):6137-49
pubmed: 23514895
Nat Med. 2009 Aug;15(8):893-900
pubmed: 19543283
J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35
pubmed: 23018371
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
mBio. 2019 Aug 20;10(4):
pubmed: 31431552
Nat Commun. 2014 Nov 10;5:5407
pubmed: 25382623
PLoS Pathog. 2010 Jan 29;6(1):e1000747
pubmed: 20126441
J Virol. 2020 Oct 14;94(21):
pubmed: 32817214
AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):183-9
pubmed: 9462929
Clin Infect Dis. 2021 Mar 02;:
pubmed: 33677480
Nature. 2009 Mar 12;458(7235):206-10
pubmed: 19078956
J Infect Dis. 2016 Dec 15;214(12):1822-1825
pubmed: 27683820
Nature. 2020 Feb;578(7793):160-165
pubmed: 31969707
Annu Rev Immunol. 2000;18:665-708
pubmed: 10837072
Annu Rev Med. 2018 Jan 29;69:421-436
pubmed: 29099677
Nat Med. 2018 Sep;24(9):1430-1440
pubmed: 30082858
J Infect Dis. 2017 Mar 15;215(suppl_3):S142-S151
pubmed: 28520967
JCI Insight. 2020 Oct 15;5(20):
pubmed: 33055422
Immunity. 2017 Oct 17;47(4):776-788.e5
pubmed: 29045906
J Virol. 2016 Jul 11;90(15):6699-6708
pubmed: 27170752
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31501143
PLoS Pathog. 2013;9(5):e1003398
pubmed: 23737751
J Virol. 2015 Sep;89(17):8677-86
pubmed: 26063417
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
AIDS. 2014 Sep 24;28(15):2251-8
pubmed: 25022595
Nat Rev Immunol. 2018 Feb;18(2):91-104
pubmed: 28990586
PLoS Pathog. 2012;8(6):e1002774
pubmed: 22737073
PLoS Med. 2017 Nov 7;14(11):e1002417
pubmed: 29112956
Nat Med. 1999 May;5(5):512-7
pubmed: 10229227
AIDS Res Hum Retroviruses. 2017 Aug;33(8):843-858
pubmed: 28503929
Nature. 2018 Nov;563(7731):360-364
pubmed: 30283138
J Virol. 2020 Dec 22;95(2):
pubmed: 33087463
Tissue Antigens. 2007 Mar;69(3):212-9
pubmed: 17493144
J Clin Invest. 2015 Dec;125(12):4497-513
pubmed: 26551680
J Infect Dis. 2015 Nov 1;212(9):1361-5
pubmed: 25877550
AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8
pubmed: 26150024
J Virol. 2019 Jul 17;93(15):
pubmed: 31118264
J Virus Erad. 2016 Oct 5;2(4):219-226
pubmed: 27781104
J Virol. 2018 May 14;92(11):
pubmed: 29563297
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
J Virol. 2014 Jul;88(14):8077-90
pubmed: 24807714
J Virol. 2020 Sep 15;94(19):
pubmed: 32669328
PLoS Pathog. 2019 Jul 10;15(7):e1007869
pubmed: 31291371
J Virol. 2021 Mar 3;:
pubmed: 33658341
Nat Commun. 2021 Mar 5;12(1):1474
pubmed: 33674572
Sci Transl Med. 2021 Jun 23;13(599):
pubmed: 34162752
J Neurovirol. 2005 Apr;11(2):180-9
pubmed: 16036796
Immunology. 2005 Jun;115(2):206-14
pubmed: 15885126
AIDS Res Hum Retroviruses. 2018 Nov;34(11):993-1001
pubmed: 29869527
AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):243-51
pubmed: 11177407
J Virol. 2009 Sep;83(18):9247-57
pubmed: 19570871
JCI Insight. 2019 Jun 6;4(11):
pubmed: 31167974